A recent surge in interest in T cell engagers, a type of antibody engineered to redirect the immune system’s T cells to recognize and kill cancer cells, suggests that this field is set to take off. Several biotech companies have launched specifically to develop these medicines, and big names in the industry are investing in them. This could lead to multiple T cell engager drugs hitting the market in the near future, offering new hope for cancer patients.
Forecast for 6 months: Expect to see at least one more biotech company launch specifically to develop T cell engagers, and several existing companies to announce positive data from their ongoing trials.
Forecast for 1 year: At least two T cell engager drugs will receive FDA approval, and several more will enter phase 3 clinical trials.
Forecast for 5 years: T cell engagers will become a standard treatment option for several types of cancer, and several companies will have established themselves as leaders in this field.
Forecast for 10 years: T cell engagers will have revolutionized cancer treatment, and several new types of cancer will have been cured or significantly improved using these medicines.
